Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BridgeBio Pharma, Inc.

http://bridgebio.com/

Latest From BridgeBio Pharma, Inc.

Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Companies Clinical Trials

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

Commercial Gene Therapy

AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance

The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.

Rare Diseases Deals

EU Accelerated Assessment Tracker

The filing for Origin Biosciences’ fosdenopterin (Nulibry) is being fast-tracked at the European Medicines Agency. The outcomes of accelerated assessment requests from Janssen and Sanofi for teclistamab and nirsevimab respectively appear not yet to be in the public domain.

Europe European Performance Tracker
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Adrenas Therapeutics
    • Aspa Therapeutics
    • Audition Therapeutics
    • Calcilytix Therapeutics
    • CoA Therapeutics
    • Fortify Therapeutics
    • Origin Biosciences
    • Phoenix Tissue Repair, Inc.
    • QED Therapeutics
    • Retinagenix LLC
UsernamePublicRestriction

Register